Audit: QRS - Thunder God Vine for Health & Longevity

Audit conducted on 21/08/2026 11:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (1–1.5 mg/kg/day, 10–20 mg three times daily, up to 3 months), time-to-effect values, benefit/risk tier items, contraindications, interactions, all 13 biomarker rows and the cadence trace to ER lines 381, 393, 397, 440, 158–214, 236–304, 328–357, 468–484.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No empty-state or hedged ER phrasing was carried into the QRS in altered form; AMH target retains the ER’s “No universal target” hedge (QRS line 740 vs ER line 482).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain absolute framing (“Pregnancy and breastfeeding”, “Statins, particularly atorvastatin, at full dose” — ER lines 334, 350); no caution is escalated or de-escalated.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All [stop_items] come from the ER “Populations who should avoid” list plus the ER’s own “Absolute contraindication” statin bullet; all [caution_items] come from the ER interaction bullets. No Benefit- or Risk-Modifying Factor was surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s blunt, evidence-weighted register (“Not a gentle herb”, ER line 519).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified thresholds and targets throughout, presented neutrally without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is descriptive throughout; no imperative instructions to a reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend”, “advise” or “consult” appears in QRS body content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Gates, protocol cells and monitoring rows state facts and values only.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain-language glosses carried from the ER where available (“low sperm count” for oligospermia, “chronic hives” for urticaria).
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit and risk is a compressed noun phrase; monitoring “Why” cells are trimmed from the ER’s full sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes a reader capable of acting on baseline panels, thresholds and course ceilings.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Three-times-daily dosing, a 13-marker panel and a front-loaded testing cadence are presented without hedging on burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content density and monitoring demands exceed general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	[at_a_glance] leads with the immunosuppressant framing and closes on trial-quality weakness, mirroring the ER’s own weighting for a risk-aware reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“premature ovarian insufficiency”, “bone-marrow suppression”, “gastrointestinal intolerance”); the plainer terms used (“hives”, “gut”) are the ER’s own headings and conclusion wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified byte-identical to the template at QRS lines 444, 484, 528, 592, 615, 619–621, 781, 552, 568 and the four tier labels in both Benefits and Risks.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 concrete template variables present; the four repeatable placeholders (marker_#name/target/why, qualitative_item#) are expanded to 13 marker rows and 7 qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes confined to checklist-addressed variables; the non-variable website="evidence_review", website="audit" and website="full_review" spans, the CSS block and the footer disclaimer are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty; every source section is populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Interaction gate items reuse the ER bold labels verbatim (“CYP3A4 inhibitors …”, “Methotrexate and leflunomide”, “Ciclosporin, tacrolimus and mycophenolate” — ER lines 328, 336, 346).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk items reuse ER sub-heading wording; monitoring marker names match the ER biomarker table column verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ “Conflicted” flags were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum the fidelity rules allow — mechanistic rationale, effect sizes and trailing em-dash clauses are stripped throughout, and monitoring “Why” cells are reduced to short phrases.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	QRS lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed entirely within the HTML comment; no metadata value is repeated in the header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: thunder_god_vine_2026-0825-0941_Opus_ER.md at line 4.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 at line 5, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0821-1052 at line 6.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus at line 7.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 at line 8.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: thunder_god_vine_2026-0825-0941_Opus_QRS.html at line 9, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Thunder God Vine for Health & Longevity - Quick Reference Sheet” (QRS line 22) matches ER canonical_topic (ER line 8) with & encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Thunder God Vine for Health & Longevity” at QRS line 417.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0821 → “08/21/2026” at QRS line 421.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” at QRS line 425.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (QRS lines 415–428) is structurally identical to the template; the ER’s alternate_names line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Every clause maps to the ER Conclusion (ER lines 519–523): potency framing, joint-disease strength, kidney and lupus effects, leading harms, reversibility, evidence-quality caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“Not a gentle herb” (ER 519), “matched or beat standard drug comparators” (519), “structural joint damage over two years” (519), “lowers protein loss … reduces lupus activity” (519), “leading adverse effect” (521), “Most reverse on stopping” (521), “weakest link” (523).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; wording is plain throughout (“immune-suppressing root”, “kidney protein loss”, “bone-marrow injury”).
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates; “two-year” is a duration, not an effect size.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items originate in ER lines 328–357.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER “Populations who should avoid” bullets (ER lines 350–357) are present, plus the ER’s explicit “Absolute contraindication at full statin dose” (ER line 334).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine <li> elements at QRS lines 555–563.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped throughout (“causes fetal malformation …”, “in whom gonadal development is at risk”, “given reversible but slow-recovering … suppression”); no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: “within 12 months”, “Child-Pugh B/C, or enzymes above twice normal”, “eGFR below 45 mL/min/1.73 m²”, “white cells 4.0, neutrophils 2.0, platelets 100 × 10⁹/L”, “under 18 years”, “at full dose”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses; thresholds are written out in words (“above twice the upper limit of normal”, “Child-Pugh Class B or C”).
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies nine such scenarios and the section is correctly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items originate in ER lines 328–346.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ER’s ten interaction bullets are present; the tenth (statins, ER line 334) is correctly excluded here because it is carried as a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements at QRS lines 571–582.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All mechanistic rationale, fold-change exposure data and mitigation advice from ER lines 328–346 are stripped; only the labelled interaction and its example list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every example list is retained; two are trimmed for budget (tizanidine dropped from the substrate list, black cohosh from the hepatotoxic botanicals) without dropping the parenthetical.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets contain no ranking notation; all parentheticals are plain comma-separated drug lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten interactions and the section is correctly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from the ER Therapeutic Protocol section (ER lines 381, 393, 397) with the dosing regimen at ER line 381.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Frequency and Course length are the three decision-critical implementation variables in the ER’s standard regimen bullet.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“1–1.5 mg/kg/day” and “10–20 mg three times daily with food” (ER 381); “away from bedtime” (ER 455) and “single large doses raise peak concentration” (ER 397); “up to three months before reassessment” (ER 381) with cycling practice (ER 418).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Joint symptoms (4–6 weeks), trial response endpoints (12 and 24 weeks) and urinary protein (3 months) are exactly the three aspects the ER states at line 440.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Both underlying benefits are High-tier; the two rheumatoid-arthritis timepoints precede the chronic-kidney-disease timepoint, matching the ER’s own benefit ordering (ER lines 160, 166).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER mentions three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated from ER line 440; sub-lines paraphrase the ER’s own clauses without adding new facts.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER line 440), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine items map to ER sub-headings at lines 160, 166, 174, 180, 188, 194, 200, 208, 212.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (QRS lines 530, 534, 538, 542) with 2 / 2 / 3 / 2 items, matching the ER tier counts exactly.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER sub-heading reduced to a noun phrase; no ACR50/ACR20 figures, mean differences, relative risks or trial counts carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven items map to ER sub-headings at lines 238, 244, 250, 256, 264, 270, 276, 284, 290, 298, 302.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (QRS lines 594, 598, 602, 606) with 4 / 3 / 2 / 2 items, matching the ER tier counts exactly.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Incidence figures (14%, 4%, 7%, 5.81%, 6%), confidence intervals and relative risks from ER lines 242–288 are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s ⚠️ Conflicted flags are also correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 470–484).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 13 ER biomarkers present in ER order: ALT, AST, total bilirubin, creatinine/eGFR, urine ACR, white cell count with neutrophils, platelets, hs-CRP, ESR, FSH, AMH, semen analysis, hepatitis B surface antigen. Targets match the ER verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 772–775 reproduce the ER’s front-loaded schedule (baseline; weeks 2 and 4; every 4 weeks; every 8–12 weeks on later courses; weeks 12 and 24) from ER lines 466–468.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER’s qualitative-marker list at ER lines 489–495.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present in ER order: morning stiffness, joint pain/swelling, menstrual cycle, appetite/nausea/bowel pattern, energy and exercise tolerance, skin/pigmentation/hair, minor infection frequency.

Issues 21/08/2026 11:57

Pass rate 100.00%. No issues found.

Issues 21/08/2026 11:50

1. 4.2 / 4.3 — Interaction label abbreviated: The Key Interactions item at line 580 reads “Immune-suppressing supplements”, but the ER’s bold label at line 344 is “Immune-suppressing and anti-inflammatory supplements”; dropping “and anti-inflammatory” abbreviates the label and mislabels the listed examples (omega-3, curcumin, resveratrol, cat’s claw, boswellia), which are anti-inflammatory rather than immunosuppressant agents.

Fixes 21/08/2026 11:50

1. 4.2 / 4.3 — Interaction label restored verbatim: The Key Interactions item was changed from “Immune-suppressing supplements” to the ER’s bold label “Immune-suppressing and anti-inflammatory supplements”, with the example drug list left intact.

Issues 21/08/2026 11:42

1. 1.3 — Hedge dropped on platelet rationale: marker_7_why (line 699) reads “Second marrow marker; moves first”, strengthening the ER’s hedged “often moving before white cells” (ER line 478) into a categorical claim.
2. 8.5 — eGFR threshold unit truncated: The contraindication at line 558 states “eGFR below 45 mL/min” instead of the ER’s “45 mL/min/1.73 m²” (ER line 353), while marker_4_target (line 663) keeps the full unit.

Fixes 21/08/2026 11:42

1. 1.3 — Platelet hedge restored: marker_7_why changed from “Second marrow marker; moves first” to “Second marrow marker; often moves first”, restoring the ER’s hedge “often moving before white cells”.
2. 8.5 — eGFR threshold unit restored: The kidney contraindication now reads “eGFR below 45 mL/min/1.73 m²” instead of “eGFR below 45 mL/min”, matching the ER threshold and the monitoring row’s unit.

Issues 21/08/2026 11:36

1. 4.3 — Monitoring row labels abbreviated: Three marker_#_name labels are shortened away from the ER Biomarker column — line 671 “Urine albumin/creatinine” (ER: “Urine albumin-to-creatinine ratio”), line 682 “White cells with neutrophils” (ER: “White cell count with neutrophils”) and line 748 “Semen concentration, motility” (ER: “Semen analysis — concentration and motility”).

Fixes 21/08/2026 11:36

1. 4.3 — Monitoring row labels restored: Restored the three abbreviated marker_#_name labels to the ER Biomarker column wording — “Urine albumin/creatinine” to “Urine albumin-to-creatinine ratio”, “White cells with neutrophils” to “White cell count with neutrophils”, and “Semen concentration, motility” to “Semen analysis — concentration and motility”.

Issues 21/08/2026 11:22

1. 4.5 — Sheet overflows the A4 budget: The stacked content measures roughly 1950 px against the ~1032 px printable column the @media print rule allows, so the sheet runs to about two pages; the Monitoring card (~640 px, QRS 621–796), the two decision gates (~340 px, QRS 553–589) and the Qualitative card (~185 px, QRS 802–830) carry most of the excess, largely through cells that wrap to a second line.
2. 10.4 — action_3_sub duplicates action_3_value: action_3_sub at QRS 478–479 restates “Up to 3 months” from action_3_value before adding “cycling is standard practice”, which comes from the ER Discontinuation & Cycling section (ER 418) rather than the ER Protocol section.

Fixes 21/08/2026 11:22

1. 4.5 — Monitoring table condensed: Trimmed the marker names, targets and “Why” cells that wrapped to a second line (e.g. “Urine albumin-to-creatinine ratio” to “Urine albumin/creatinine”, “Rising values signal ovarian suppression, the leading adverse effect” to “Rising values signal ovarian suppression”), removing roughly eleven wrapped lines from the tallest card.
2. 4.5 — Decision gates condensed: Shortened five contraindication items and two interaction items (e.g. “Child-Pugh B or C cirrhosis, or liver enzymes above twice normal” to “Child-Pugh B/C, or enzymes above twice normal”), while keeping every threshold, time window and named example drug.
3. 4.5 — Monitoring cadence condensed: Tightened the cadence sentence (“full blood count” to “blood count”, “every 8–12 weeks on any subsequent course” to “every 8–12 weeks on later courses”) with all checkpoints preserved.
4. 10.4 — action_3_sub no longer duplicates its value: Replaced “Up to three months, then a break; cycling is standard practice” with “Continuous course, then reassessment; short intermittent courses favoured”, both clauses now drawn from the ER Therapeutic Protocol section.

Issues 21/08/2026 11:17

1. 4.5 — Sheet overflows the A4 budget: Rendered content runs to roughly twice one A4 page — the 13-row Monitoring table (lines 623–791) mostly wraps to two lines per row, the two decision gates carry about 35 wrapped lines (lines 555–590), and each of the seven Qualitative items (lines 805–832) wraps to two lines; sections were transcribed at ER length instead of condensed to the per-section budget.
2. 2.8 — ER explanatory clauses not condensed: The seven qualitative_item_* spans (lines 806–831) retain the ER’s full trailing rationale clauses, and several gate items and Monitoring “why” strings remain at full ER sentence length rather than being compacted.

Fixes 21/08/2026 11:17

1. 4.5 — Monitoring table condensed to single-line rows: Shortened the “why” text of markers 3–13 (e.g., “Tracks the primary benefit in kidney disease and detects new filtration-barrier injury” → “Tracks the kidney benefit and new filtration-barrier injury”) and trimmed marker_11_target to “No universal target — track change from own pre-treatment value”, cutting most rows from two rendered lines to one.
2. 4.5 / 2.8 — Qualitative items stripped to the marker: Removed the ER’s trailing rationale clauses from qualitative_item_1 and qualitative_item_3 through qualitative_item_7 (e.g., “Energy levels and exercise tolerance, which distinguish disease control from the fatigue of anaemia or marrow suppression” → “Energy levels and exercise tolerance”), halving the section’s height.
3. 4.5 — Decision gates tightened: Compacted five Contraindication and three Key Interaction items (e.g., “Child-Pugh Class B or C cirrhosis, or liver enzymes above twice the upper limit of normal” → “Child-Pugh B or C cirrhosis, or liver enzymes above twice normal”; “Immune-suppressing and anti-inflammatory supplements” → “Immune-suppressing supplements”) while preserving every threshold and named example drug.
4. 4.5 — Protocol and Time-to-effect subtexts shortened: Trimmed action_2_sub, action_3_sub, time_2_sub and time_3_sub (e.g., “Courses of up to three months before reassessment, then a break; cycling is standard practice” → “Up to three months, then a break; cycling is standard practice”).
5. 4.5 / 2.8 — Cadence and High-risk row compacted: Reworded monitoring_cadence to “Baseline panel; … at weeks 2 and 4 … at weeks 12 and 24” and changed the High risk entry’s “suppression of sperm production” to “suppressed sperm production” to drop a wrapped line.

Issues 21/08/2026 11:11

1. 2.5 — Directive phrasing in Protocol sub: [action_2_sub] (line 466) reads “Always split, taken with food, away from bedtime; single large doses raise peak concentration”; the opening imperative instructs rather than presents the ER’s finding.

Fixes 21/08/2026 11:11

1. 2.5 — Directive phrasing in Protocol sub: Rewrote [action_2_sub] from “Always split, taken with food, away from bedtime; single large doses raise peak concentration” to “Split dosing with food, away from bedtime; single large doses raise peak concentration”, removing the imperative opening.

Issues 21/08/2026 11:05

1. 11.4 — Tautological time-to-effect sub: [time_2_sub] at QRS lines 508–509 reads “Points at which trial response endpoints were measured”, which only restates [time_2_label] “Trial response endpoints” and adds no information beyond the label and the “12 and 24 weeks” value.
2. 12.3 — Qualifier appended to benefit item: [benefits_low] at QRS line 541 carries “(conflicted)” on “reduced ankylosing spondylitis symptoms”, a qualifier the section headnote treats as redundant because the Low tier already encodes evidence strength.
3. 13.3 — Qualifier appended to risk item: [risks_medium] at QRS line 607 carries “(conflicted)” on “infection from immune suppression”, a qualifier the section headnote treats as redundant because the Medium tier already encodes evidence strength.

Fixes 21/08/2026 11:05

1. 11.4 — Tautological time-to-effect sub: Replaced [time_2_sub] “Points at which trial response endpoints were measured” with “Joint response and disease-activity scoring are assessed at these points”, so the sub adds information instead of restating the label.
2. 12.3 / 13.3 — Redundant evidence qualifiers stripped: Removed the trailing “(conflicted)” from “reduced ankylosing spondylitis symptoms” in [benefits_low] and from “infection from immune suppression” in [risks_medium], leaving the Low and Medium tiers to carry the evidence strength.

Issues 21/08/2026 10:59

1. 2.7 — Unexpanded jargon in contraindications: The Contraindications gate uses “oligospermia” (QRS line 566) and “cytopenia” (QRS line 561) without the plain-language expansions the ER itself supplies at ER lines 356 and 354 (“low sperm count”, “low blood counts”), leaving specialist terms in a decision gate whose whole purpose is that a non-specialist can self-assess against it.

Fixes 21/08/2026 10:59

1. 2.7 — Unexpanded jargon in contraindications: Replaced the two bare specialist terms in the Contraindications gate with the ER’s own plain-language wording — “Baseline cytopenia” became “Baseline low blood counts” and “pre-existing oligospermia” became “pre-existing low sperm count”, with the numeric thresholds left untouched.